Anixa Biosciences presents updated positive Phase 1 data for breast cancer vaccine; Phase 2 planned for 2025

Anixa Biosciences Inc

Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.
Vaccine safe and well tolerated; only notable side effect was injection-site irritation.
Over 70% of patients exhibited protocol-defined immune responses (interferon-gamma, interleukin-17).
Combination with Keytruda (Cohort 1c) showed no major adverse events; one Grade 3 injection-site reaction in a recently lactated patient.
Phase 2 neoadjuvant study with randomized control planned to commence in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.